D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study.
Saad Usmani,Hang Quach,Maria-Victoria Mateos,Ola Landgren,Xavier Leleu,David Spiegel,Katja Weisel,Xiao-Ou Shu,Chuang Li,Meletios A. Dimopoulos +9 more
TL;DR: CANDOR as mentioned in this paper is a randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) in adults with relapsed/refectory multiple myeloma (RRMM) with 1-3 prior therapies.
Journal ArticleDOI
Abstract CT152: Phase I study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing advanced solid tumors
David Spiegel,E. Ahn,Herb Duvivier,Drew W. Rasco,Agnes Rethy,Chris Moore,Amy Yuet,Sandra Hankins,Swati Khanna,Joseph Dekker,Brian A. Van Tine +10 more
TL;DR: The results support further dose escalation and hold promise for development of MT-6402 for solid tumors, including in the R/R setting, and describe a novel approach to checkpoint modulation, leveraging direct PD-L1 cell kill and antigen seeding technology by the ETB.
Journal ArticleDOI
Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.
Emma G. Sturgill,Sahiti Kolli,Kavanya Feustel,Daniel Luckett,Carissa Maree. Jones,Marilyn E. Holt,Annastasia S. Hyde,Suzanne F. Jones,Cesar A. Perez,Judy Wang,Stephen G. Divers,Meredith S. Pelster,JF Henry,David Spiegel,Howard A. Burris Iii,Andrew J. McKenzie +15 more
TL;DR: In this paper , the authors conducted a retrospective, records-based analysis of 2,805 patients with PDAC from across 299 community-based oncology clinics and assessed for co-mutations, overall survival, and time to chemotherapy failure.
Journal ArticleDOI
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
David Spiegel,Maen A. Hussein,Richard Zuniga,Daruka Mahadevan,Robert K. Winn,Walter C. Darbonne,Bongin Yoo,Zach Whitehead,Ari M. Vanderwalde +8 more
TL;DR: The efficacy and safety of atezo + chemo in patients with TMB-H and/or MSI-H/dMMR were evaluated in a phase II, non-randomized, multi-arm basket study as mentioned in this paper .